Innoviva Competitors
| INVA Stock | USD 20.00 0.25 1.27% |
Innoviva vs Dianthus Therapeutics Correlation
Modest diversification
The correlation between Innoviva and DNTH is 0.22 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Innoviva and DNTH in the same portfolio, assuming nothing else is changed.
Moving against Innoviva Stock
At present, Innoviva's Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Equity is forecasted to decline to 0.03. At present, Innoviva's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 901.7 M, whereas Other Assets are forecasted to decline to about 131.6 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Innoviva's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Innoviva Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Innoviva and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Innoviva and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Innoviva does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Innoviva Stock performing well and Innoviva Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Innoviva's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MDXG | 2.04 | (0.41) | 0.00 | (1.20) | 0.00 | 3.57 | 12.42 | |||
| NKTR | 3.70 | (0.65) | 0.00 | (0.84) | 0.00 | 6.56 | 20.31 | |||
| ATAI | 2.57 | (0.63) | 0.00 | (1.13) | 0.00 | 4.91 | 16.19 | |||
| SNDX | 2.72 | 0.66 | 0.31 | 0.51 | 1.87 | 8.70 | 18.37 | |||
| INBX | 3.01 | 0.34 | 0.08 | (28.81) | 3.63 | 6.04 | 23.28 | |||
| IMTX | 3.01 | 0.01 | 0.00 | 0.07 | 3.86 | 7.31 | 30.34 | |||
| CVAC | 1.22 | (0.22) | 0.00 | (0.57) | 0.00 | 3.33 | 18.10 | |||
| ELVN | 4.15 | 0.56 | 0.12 | 0.34 | 4.51 | 6.50 | 54.92 | |||
| RLAY | 3.00 | 0.19 | 0.04 | 0.57 | 3.35 | 6.11 | 30.68 | |||
| DNTH | 2.74 | 0.81 | 0.25 | (1.19) | 2.25 | 8.00 | 22.10 |
Cross Equities Net Income Analysis
Compare Innoviva and related stocks such as MiMedx Group, Nektar Therapeutics, and ATAI Life Sciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDXG | (16.7 K) | (10.2 M) | (7.7 M) | (4.1 M) | 6.2 M | 29.4 M | 12 M | 64.7 M | (30 M) | (30 M) | (49.3 M) | (12.3 M) | (30.2 M) | 67.4 M | 42.4 M | 48.8 M | 51.2 M |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| ATAI | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (169.8 M) | (167.8 M) | (152.4 M) | (40.2 M) | (149.3 M) | (134.3 M) | (141.1 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (75.6 M) | (81.8 M) | (145.2 M) | (241.4 M) | 1.7 B | 1.9 B | 2 B |
| IMTX | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.7 M) | (229.3 M) | (95.1 M) | 37.5 M | (97 M) | 15.2 M | 17.5 M | 18.4 M |
| CVAC | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (99.9 M) | (129.1 M) | (411.7 M) | (249 M) | (260.2 M) | 162.2 M | 186.5 M | 195.8 M |
| ELVN | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (23.5 M) | (19 M) | (24.7 M) | (37.7 M) | (71.6 M) | (89 M) | (80.1 M) | (76.1 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| DNTH | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (35.5 M) | (57.5 M) | (76.8 M) | (74.9 M) | (13.1 M) | (28.5 M) | (43.6 M) | (85 M) | (76.5 M) | (72.6 M) |
Innoviva and related stocks such as MiMedx Group, Nektar Therapeutics, and ATAI Life Sciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Innoviva financial statement analysis. It represents the amount of money remaining after all of Innoviva operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Innoviva Competitive Analysis
The better you understand Innoviva competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Innoviva's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Innoviva's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Innoviva Competition Performance Charts
Five steps to successful analysis of Innoviva Competition
Innoviva's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Innoviva in relation to its competition. Innoviva's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Innoviva in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Innoviva's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Innoviva, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Innoviva position
In addition to having Innoviva in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Processed Foods Thematic Idea Now
Processed Foods
Companies producing and distributing processed foods to retail sectors. The Processed Foods theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Processed Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Innoviva Correlation with its peers. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. Market participants price Innoviva higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innoviva assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 54.789 | Earnings Share 1.66 | Revenue Per Share | Quarterly Revenue Growth 0.204 | Return On Assets |
Understanding Innoviva requires distinguishing between market price and book value, where the latter reflects Innoviva's accounting equity. The concept of intrinsic value—what Innoviva's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Innoviva's price substantially above or below its fundamental value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Innoviva's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.